Shanghai Qilu Pharmaceutical Research and Development Center LTD clinical trials
A subsidiary of Qilu Pharmaceutical Co., Ltd.
The registry lists 5 studies whose lead sponsor is Shanghai Qilu Pharmaceutical Research and Development Center LTD. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 13, 2026.
Registry sponsor names on this page
- Shanghai Qilu Pharmaceutical Research and Development Center LTD5 studies
Something wrong with this grouping? Tell us on the Qilu Pharmaceutical Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Qilu Pharmaceutical Co., Ltd. studies →
- A Study of QLS2401 Injection in Participants With Advanced Prostate CancerNot yet recruitingNCT07869888Phase 1
Sponsor listed in the registry: Shanghai Qilu Pharmaceutical Research and Development Center LTD
- A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of QLS2312 InjectionNot yet recruitingNCT07861581Phase 1
Sponsor listed in the registry: Shanghai Qilu Pharmaceutical Research and Development Center LTD
- Phase I Study of QLS1510 Tablets in Healthy ParticipantsNot yet recruitingNCT07760077Phase 1
Sponsor listed in the registry: Shanghai Qilu Pharmaceutical Research and Development Center LTD
- This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.Not yet recruitingNCT07552376Phase 1
Sponsor listed in the registry: Shanghai Qilu Pharmaceutical Research and Development Center LTD
- A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis PatientsRecruitingNCT06946641Phase 1
Sponsor listed in the registry: Shanghai Qilu Pharmaceutical Research and Development Center LTD